RATIONAL PHARMACOTHERAPY OF THE SYMPTOMATIC UNCOMPLICATED COLON DIVERTICULAR DISEASE

The article presents the results of long-term monitoring of patients diverticular disease of the colon to study the effectiveness of different groups of medicines on the basis of which the proposed rational scheme of treatment according to age of patients, duration of anamnesis of disease and presence of comorbidities. In the period 2003-2016 the study included 396 patients aged 24 to 89 years (mean age 61,4±9.3 years) with instrumental confirmed diverticula of the colon. A big problem in the elderly is polymorbidity and, as a result, forced polypragmasia. In our study of 295 patients over 60 years of age at the time of inclusion in the study had 4.7-5.2 diseases per 1 person. The most common were systemic atherosclerosis, constipation and hyperlipidemia. Constipation was detected in 193 patients (65.4%), hyperlipidemia - in 170 (57.6%). Drugs psillium and lactulose have long been widely known as effective laxatives with prebiotic properties and safe with long-term use. In our study, 120 patients took psyllium and 116-lactulose. For two years, we estimated the number of relapses of NSC (resumption of pain and symptoms of intestinal dyspepsia). It was found that in the psyllium group during the two-year follow-up period the number of recurrences was 20% less than in the lactulose group. Summary. The most effective drug for relief of abdominal pain syndrome in patients with diverticular disease of the colon in all age groups is trimebutin In the treatment of symptomatic diverticular disease of the colon in patients younger than 45 years, it is advisable to prescribe intestinal antiseptics (rifaximin, nifuroxazide) for at least 7 days from the moment of treatment. Patients over 75 years of age need normalization of the stool with the predominant use of laxatives with prebiotic action. When combined with diverticular disease and constipation hyperlipidemia drug of choice is psyllium (mukofalk, vibrolux). At presence at patients of senile age concomitant cardiovascular pathology with the purpose of correction of possible ischemia of the bowel wall at the microscopic level should be provided citoprotected drug of butyric acid

diverticular disease of the colon conservative therapy, antispasmodics, probiotics, intestinal antiseptics, butyrat

1. Kang J.Y., Firwana B., Green A. E. et al. Uncomplicated diverticular disease is not a common cause of colonic symptoms. Aliment.Pham.Ther., 2011, Vol.33(4), P. 487-494

2. Tursi A, Papa A, Danese S. Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. Aliment Pharmacol Ther 2015; 42: 664-684

3. Viniol A, Keunecke C, Biroga T, Stadje R, Dornieden K, Bösner S, Donner-Banzhoff N, Haasenritter J, Becker A Studies of the symptom abdominal pain-a systematic review and meta-analysis. Fam Pract. 2014 Oct;31(5):517-29. doi: 10.1093/fampra/cmu036.

4. Bevan R, Lee T.J, Nickerson C, Rubin G, Rees C.J; NHS BCSP Evaluation Group. Non-neoplastic findings at colonoscopy after positive faecal occult blood testing: data from the English Bowel Cancer Screening Programme. J Med Screen 2014; 21: 8994.

5. Клинико-морфологические варианты дивертикулярной болезни толстой кишки. Левченко С. В., Лазебник Л. Б., Потапова В. Б., Рогозина В. А. Экспериментальная и клиническая гастроэнтерология 2013 № 3:23-30

6. Strate L.L, Modi R, Cohen E, Spiegel B.M. Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. Am J Gastroenterol 2012; 107: 1486-1493

7. Morris A.M, Regenbogen S.E, Hardiman K.M, Hendren S Sigmoid diverticulitis: a systematic review. JAMA. 2014 Jan 15;311(3):287-97. doi: 10.1001/jama.2013.282025

8. Spiller R. Is it diverticular disease or is it irritable bowel syndrome? Dig Dis 2012; 30: 64-69

9. Cuomo R, Barbara G, Andreozzi P, Bassotti G, Casetti T, Grassini M, Ierardi E, Maconi G, Marchi S, Sarnelli G, Savarino V, Usai P, Vozzella L, Annibale B. Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. Eur J Clin Invest 2013; 43: 1147-1155.

10. Tursi A. Diverticulosis today: unfashionable and still under-researched. Therap Adv Gastroenterol 2016; 9: 213-228

11. Ford A.C., Talley N. J., Spiegel B. M. et al. Effect of fiber, antispasmodics and peppermint oil in the treatment of irritable bowel syndrome: systematic review and metaanalysis. BMJ, 2008, Now, 337 doi: https://doi.org/10.1136/bmj.a2313

12. Shepberd N.A Diverticular disease in chronic idiopathic inflammatory bowel disease: associations and masquerades Gut 1996; 38:801-2.

13. Lamps L.W, Knapple W.L. Diverticular disease-associated segmental colitis. Clin Gastroenterol Hepatol 2007;5:27-31]

14. Левченко С.В., Гудкова Р. Б., Потапова В. Б., Лазебник Л. Б. Реакция иммунокомпетентных клеток и структурные изменения слизистой оболочки толстой кишки у больных дивертикулярной болезнью // Эксперим. и клинич. гастроэнтерол. 2009, - № 5. - С. 17-20

15. Минушкин О.Н., Кручинина М. А. Синдром избыточного бактериального роста у больных дивертикулярной болезнью толстой кишки. Кремлевская медицина. 2014,1:99-104

16. Попова Е.В. Нарушение состава кишечной микрофлоры в механизмах формирования клинико-морфологических проявлений у больных дивертикулярной болезнью толстой кишки. Дисс. к. м.н., 2012,121 стр

17. Комиссаренко И.А., Левченко С. В., Гудкова Р. Б., Сильвестрова С. Ю. Эффекты длительного применения псиллиума при лечении больных с дивертикулярной болезнью толстой кишки. // КПГГ, 2014:3: 29-36

18. Strate L.L., Liu Y. L., Aldoori W. H. et al. Obesity increases the risks of diverticulitis and diverticular bleeding, Gastroenterol., 2009, 136(1), P. 115-22

19. Kopylov U, Ben-Horin S, Lahat A, Segev S. Obesity, metabolic syndrome and the risk of development of colonic diverticulosis, Digestion 2012;86(3):201-5

20. Левченко С.В., Лазебник Л. Б., Потапова В. Б., Рогозина В. А. Клинико-морфологические варианты дивертикулярной болезни толстой кишки. Экспериментальная и клиническая гастроэнтерология 2013 № 3:23-20

21. Krokowicz L., Stojcev Z, Kaczmarek B.F, Kociemba W, Kaczmarek E, Walkowiak J, Krokowicz P, Drews M, Banasiewicz T. Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis - a prospective randomized study. Int J Colorectal Dis. 2014 Mar;29(3):387-93. doi: 10.1007/s00384-013-1807-5